Phathom Pharmaceuticals, Inc. (PHAT)
NASDAQ: PHAT · Real-Time Price · USD
13.56
+1.24 (10.06%)
At close: Feb 26, 2026, 4:00 PM EST
13.47
-0.09 (-0.66%)
After-hours: Feb 26, 2026, 7:38 PM EST
Phathom Pharmaceuticals Market Cap
Phathom Pharmaceuticals has a market cap or net worth of $1.06 billion as of February 26, 2026. Its market cap has increased by 187.00% in one year.
Market Cap
1.06B
Enterprise Value
1.52B
1-Year Change
187.00%
Ranking
Category
Stock Price
$13.56
Market Cap Chart
Since October 25, 2019, Phathom Pharmaceuticals's market cap has increased from $527.13M to $1.06B, an increase of 101.41%. That is a compound annual growth rate of 11.67%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 25, 2026 | 964.59M | -18.27% |
| Dec 31, 2025 | 1.18B | 112.56% |
| Dec 31, 2024 | 555.22M | 6.22% |
| Dec 29, 2023 | 522.72M | 13.23% |
| Dec 30, 2022 | 461.63M | -22.48% |
| Dec 31, 2021 | 595.53M | -36.35% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Oct 25, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Valneva SE | 997.56M |
| CytomX Therapeutics | 979.34M |
| GH Research | 976.96M |
| SpyGlass Pharma | 970.54M |
| UroGen Pharma | 967.54M |
| Theravance Biopharma | 965.82M |
| ArriVent BioPharma | 961.44M |
| Bicara Therapeutics | 959.23M |